Company: MDCXW
Filing Date: 2025-11-17
Form Type: 424B3
Source: 0001062993-25-016872
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-17
Form: 424B3
Chunk 2
---
 generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period; the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates; our ability to successfully integrate Antev Limited into our business and operations, successfully develop Teverelix trifluoroacetate and realize the benefits currently anticipated from the transaction; our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates; our ability to develop, manage and maintain our direct sales and marketing organizations; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines; our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the fact that product quality issues or product defects may harm our business; any product liability claims; and the regulatory, legal and certain operating risks that our operations subject us to. The forward-looking statements contained in this Quarterly Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in Part I, Item 1A in our Annual Report on Form 10-K, as amended, originally filed with the United States Securities and Exchange Commission ("SEC") on March 28, 2025 (the "2024 Annual Report") and in Part II, Item 1A of this Quarterly Report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. PART I - FINANCIAL INFORMATION Item 1. Interim Financial Statements. MEDICUS PHARMA LTD. CONDENSE